Ingredient review —Reishi (Ganoderma lucidum/lingzhi)
What is it?
Description
Medicinal mushrooms of the Ganoderma genus are called the “Mushrooms of Immortality” for their uses to maintain general health and increase longevity. (1)(32) In Traditional Japanese medicine or Traditional Chinese Medicine (TCM), the mushrooms are called reishi, or lingzhi, respectively. (32)
The name Ganoderma lucidum has been broadly used to describe laccate mushrooms of this family. (23) However, on a global scale, species belonging to the Ganoderma genus have been widely misclassified as lucidum species, creating confusion and possible mislabelling of Ganoderma-based products available in the dietary supplement market today. (1)(22)(23)
Strictly based on chemical composition, Ganoderma lucidum is a mushroom native to Europe, whereas Ganoderma lingzhi is native to Asia. However, products labeled as Ganoderma lucidum are frequently of the lingzhi species, the type most often cited for its medicinal effects despite its bioactive constituents’ distinct chemical compositions, known as polysaccharides and triterpenes. (17)(23)(35) Polysaccharides act primarily through immunomodulation to provide anti-bacterial, anti-oxidative, and anti-tumorous properties, whereas triterpenoids have broader anti-angiogenic, anti-histaminic, anti-hypertensive, anti-tumorous, hepatoprotective, and hypocholesterolemic properties. (8)
Notwithstanding the taxonomic-based complications of reishi-containing products, the use of Ganoderma lucidum will refer to reishi from a broad sense rather than it’s biochemical identification in this review.
Main uses
Anti-oxidant
Chemotherapy and radiotherapy adjuvant
Immunomodulation
Sense of well-being
Symptoms related to cancer (emotional, cognitive, or physical)
Formulations
Formulation
Comparison
Whole mushroom
Crude dried extract
Raw (unfractionated) extracts are not processed in a manner to isolate specific biochemical constituents. As 10% of the weight of G. lucidum are non-water constituents, crude dehydrated mushroom extracts are 10x more concentrated than the whole mushroom (e.g., 10 g of whole mushroom = 1 g crude extract) (32)
Water-soluble extracts
Primarily used to refine the polysaccharides of G. lucidum (32)
Doses found in research (see below) most often range between 1,500-3,000 mg taken in divided doses
Ethanolic extracts
Mainly used to refine the triterpenes of G. lucidum (32)
Doses found in research (see below) are much lower than water-soluble doses and listed at 6 mg per day
Ganopoly®
A water-soluble extract containing 25% weight per weight of G. lucidum polysaccharides; one capsule (600 mg) is equivalent to ~30 g of reishi fruiting body, where the total recommended daily dose (5400 mg) is equal to 270 g of whole mushroom fruiting body (12)
Ji 731 injection/ Jisheng injection/ Polysaccharidum of G. lucidum Karst Injection
Intramuscular medicine containing polysaccharides from G. lucidum spores. Approved by China’s FDA in 2000, it treats neurosis, polymyositis, dermatomyositis, atrophic myotonia, and muscular dystrophy, as well as conditions related to immunodeficiency (36)
Dosing & administration
Anti-oxidation and hepatoprotection
General outcomes from A-level evidence
No data currently available.
Dosing & administration
1,100-3,300 mg (as water-soluble G. lucidum extract) acutely, or 730 mg per day for up to 10 days to healthy Px
Outcomes
plasma total anti-oxidative capacity by ~30% within three hours (peaking at 90 mins post-ingestion), and fasting ɑ-tocopherol & urinary anti-oxidative capacity after ten days with the lower dose (31)
Class of evidence
c
Dosing & administration
225 mg (as 7% triterpenoid-ganoderic acid and 6% polysaccharide peptides enriched G. lucidum) per day for six months to healthy adults with mild liver dysfunction
Outcomes
total anti-oxidative capacity compared to placebo/baseline, & thiols and glutathione compared to baseline
TBARS and 8-OH-dG (biomarkers of oxidative stress), & glutamic oxaloacetic transaminase and glutamic pyruvic transaminase (hepatic markers) compared to placebo/baseline
Px normalized from an initially mild fatty liver (5)
Class of evidence
c
Cardiovascular disease risk factors
General outcomes from A-level evidence
No data currently available.
Dosing & administration
720 mg (water-soluble G. lucidum extract) twice per day for 12 weeks to mildly hypertensive or hyperlipidemic adults
Outcomes
HDL-C by 24%
triglycerides by 8% compared to placebo (6)
Class of evidence
c
Chemotherapy and radiotherapy response
General outcomes from A-level evidence
Dosing & administration
1,200 mg (as G. lingzhi) per day starting with radiotherapy and for one month to patients with esophageal cancer
Outcomes
rate of radiotherapy effectiveness, leukocyte and platelet counts, phagocytic activity, & survival time and rate compared with radiotherapy alone (20)
Class of evidence
c
Dosing & administration
1000 mg (as G. lucidum spore powder) three times per day for four weeks intra- or post-endocrine therapy to women with breast cancer who had previously received surgery, with or without chemotherapy or radiotherapy
Outcomes
rticularly within the physical, emotional, functional, and fatigue subscores compared to placebo
Hospital Anxiety and Depression scale compared to baseline, & IL-6 and TNF-ɑ inflammatory markers compared to placebo
Improves EORTC QOL-C30 scores for physical, emotional, and cognitive functioning, & global QoL score compared to placebo (40)
Class of evidence
c
Colorectal adenomas
General outcomes from A-level evidence
No data currently available.
Dosing & administration
750 mg (water-soluble G. lucidum mycelia extract) twice per day for 12 months
Outcomes
the number and size of adenomas compared with no treatment (26)
Class of evidence
c
Coronary heart disease
General outcomes from A-level evidence
No data currently available.
Dosing & administration
1,800 mg (as Ganopoly®) three times per day for 12 weeks
Outcomes
prevalence of chest pain, palpitation, angina, shortness of breath, abnormal ECGs, & blood pressure compared to placebo, and lower serum cholesterol compared to baseline (14)
Class of evidence
b
Fibromyalgia-related physical capacity
General outcomes from A-level evidence
No data currently available.
Dosing & administration
3,000 mg (as G. lucidum) twice per day with meals for six weeks to women with fibromyalgia
Outcomes
aerobic endurance, lower-body flexibility, & walking speed compared with Ceratonia siliqua (Carob plant) (7)
Class of evidence
c
Hepatitis B
General outcomes from A-level evidence
No data currently available.
Dosing & administration
1,800 mg (as Ganopoly®) three times per day for 12 weeks
Outcomes
proportion of Px with reduced HBeAg viral proteins & hepatitis B viral DNA compared to placebo, especially in Px with baseline AST > 100U/L
rate of normalized ALT levels in treatment group (11)
Class of evidence
b
Immunomodulation
General outcomes from A-level evidence
No data currently available.
Dosing & administration
350 mg (as beta-glucan polysaccharides derived from G. lucidum) per day in yogurt for 12 weeks to children
Outcomes
total lymphocytes, CD3+, CD4+ , & CD8+ T cells compared to placebo (16)
Class of evidence
b
Dosing & administration
2,500-5,000 mg (as water-soluble G. lucidum extract) per day for four weeks to athletes subject to high altitude sleeping conditions
Outcomes
CD3+ T cells (high dose)
Attenuates reductions in CD4:CD8 lymphocytic ratio caused by high altitudes (either dose) (39)
Class of evidence
c
Lower urinary tract symptoms
Advanced lung cancer
General outcomes from A-level evidence
No data currently available.
Dosing & administration
600 mg (as Ganopoly®) three times per day for 12 weeks
Outcomes
the proportion of Px with stable disease after 12 weeks compared to placebo, the percent of patients with positively impacted Karnofsky performance score (well-being and activity), relief from cancer-related symptoms of fever, cough, weakness, sweating, and insomnia, & immune parameters of lymphocyte mitogenic reactivity to concanavalin A, CD3 percentage, and natural killer cell activity (9)
Class of evidence
b
Neurasthenia
General outcomes from A-level evidence
No data currently available.
Dosing & administration
1,800 mg (as Ganopoly®) three times per day for eight weeks
Outcomes
clinical global impression & fatigue scores
sense of well-being (28)
Class of evidence
b
Type II diabetes
General outcomes from A-level evidence
Note: no effect was observed on cardiovascular risk factors including HbA1C, total cholesterol, LDL-C, or BMI in studies using 1,400-3,000 mg G. lucidum per day for 12-16 weeks (21)
Dosing & administration
1,800 mg (as Ganopoly®) three times per day for 12 weeks
Outcomes
HBA1C, fasting and postprandial glucose, insulin, & C-peptide (10)
Class of evidence
b
Adverse effects
G. lucidum is generally considered safe and without clinically significant adverse effects or greater prevalence of side effects than placebo. Reported possible adverse effects include mild gastrointestinal distress (e.g., nausea, diarrhea, constipation), dizziness, headache, rhinorrhea, sore throat, dry mouth, insomnia, and rash. (6)(18)(21)(24)(25)(40) G. lucidum may also induce respiratory allergy. (27)
Pharmacokinetics
Absorption
- Two G. lucidum triterpenes, Ganoderic acid A (GAA) and Ganoderic acid F (GAF), are rapidly absorbed in the gastrointestinal tract and detectable in blood within 5-10 minutes, with max concentrations reached within 30 minutes, as shown in humans. (29)(30)
- As shown in humans, GAA was better absorbed in a fasted state compared to in a fed state, but absolute bioavailability is low. This is consistent with rat studies demonstrating GAA, GAF, and ganoderic acid D absolute oral bioavailabilities of 10-22%. (4)(13)(19)(28)(30)
Metabolism
References
- Bishop, K. S., Kao, C. H. J., Xu, Y., Glucina, M. P., Paterson, R. R. M., & Ferguson, L. R. (2015). From 2000 years of Ganoderma lucidum to recent developments in nutraceuticals. Phytochemistry, 114, 56–65. ()
- Cao, F. R., Feng, L., Ye, L. H., Wang, L. S., Xiao, B. X., Tao, X., & Chang, Q. (2017). Ganoderic acid a metabolites and their metabolic kinetics. Frontiers in Pharmacology, 8, 101. ()
- Chen, X., Hu, Z. P., Yang, X. X., Huang, M., Gao, Y., Tang, W., Chan, S. Y., Dai, X., Ye, J., Ho, P. C.-L., Duan, W., Yang, H.-Y., Zhu, Y.-Z., & Zhou, S.-F. (2006). Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. International Immunopharmacology, 6(3), 499–508. ()
- Cheng, C. R., Yang, M., Guan, S. H., Wu, X. H., Pang, X. Y., Wang, Y., Yang, Y., Ding, J., & Guo, D. A. (2013). Pharmacokinetics of ganoderic acid D and its main metabolite by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B, 930, 1–6. ()
- Chiu, H. F., Fu, H. Y., Lu, Y. Y., Han, Y. C., Shen, Y. C., Venkatakrishnan, K., Golovinskaia, O., & Wang, C. K. (2017). Triterpenoids and polysaccharide peptides-enriched Ganoderma lucidum: A randomized, double-blind placebo-controlled crossover study of its antioxidation and hepatoprotective efficacy in healthy volunteers. Pharmaceutical Biology, 55(1), 1041–1046. ()
- Chu, T. T. W., Benzie, I. F. F., Lam, C. W. K., Fok, B. S. P., Lee, K. K. C., & Tomlinson, B. (2012). Study of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): Results of a controlled human intervention trial. The British Journal of Nutrition, 107(7), 1017–1027. ()
- Collado Mateo, D., Pazzi, F., Domínguez Muñoz, F. J., Martín Martínez, J. P., Olivares, P. R., Gusi, N., & Adsuar, J. C. (2015). Ganoderma lucidum improves physical fitness in women with fibromyalgia. Nutricion Hospitalaria, 32(5), 2126–2135. ()
- Cör, D., Knez, Ž., & Knez Hrnčič, M. (2018). Antitumour, antimicrobial, antioxidant and antiacetylcholinesterase effect of ganoderma lucidum terpenoids and polysaccharides: A review. Molecules , 23(3). ()
- Gao, Y., Dai, X., Chen, G., Ye, J., & Zhou, S. (2003). A randomized, placebo-controlled, multicenter study of Ganoderma lucidum (w.curt.:fr.) lloyd (aphyllophoromycetideae) polysaccharides (Ganopoly®) in patients with advanced lung cancer. International Journal of Medicinal Mushrooms, 5(4). ()
- Gao, Y., Lan, J., Dai, X., Ye, J., & Zhou, S. (2004). A phase i/ii study of ling zhi mushroom Ganoderma lucidum (w.curt.:fr.)lloyd (aphyllophoromycetideae) extract in patients with type II diabetes mellitus. International Journal of Medicinal Mushrooms, 6(1). ()
- Gao, Y., Zhou, S., Chen, G., Dai, X., Ye, J., & Gao, H. (2002). A phase i/ii study of a Ganoderma lucidum (curt.: fr.) p. karst. (ling zhi, reishi mushroom) extract in patients with chronic hepatitis B. International Journal of Medicinal Mushrooms, 4(4). ()
- Gao, Y., Zhou, S., Jiang, W., Huang, M., & Dai, X. (2003). Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunological Investigations, 32(3), 201–215. ()
- Gao, J. J., Min, B. S., Akao, T., Meselhy, M. R., Nakamura, N., & Hattori, M. (2001). Enzyme immunoassay for the quantitative determination of ganoderic acid A from Ganoderma lucidum. Journal of Traditional Medicine, 18, 154–160. ()
- Gao, Y., Chen, G., Daiy, X., Yey, J., & Zhou, S. (2003). A phase i/ii study of ling zhi mushroom Ganoderma lucidum (w.curt.:fr.) lloyd (aphyllophoromycetideae) extract in patients with coronary heart disease. International Journal of Medicinal Mushrooms, 6(4), 327–334. ()
- Guo, X. Y., Han, J., Ye, M., Ma, X. C., Shen, X., Xue, B. B., & Che, Q. M. (2012). Identification of major compounds in rat bile after oral administration of total triterpenoids of Ganoderma lucidum by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 63, 29–39. ()
- Henao, S. L. D., Urrego, S. A., Cano, A. M., & Higuita, E. A. (2018). Randomized clinical trial for the evaluation of immune modulation by yogurt enriched with β-glucans from lingzhi or reishi medicinal mushroom, Ganoderma lucidum (agaricomycetes), in children from Medellin, Colombia. International Journal of Medicinal Mushrooms, 20(8), 705–716. ()
- Hennicke, F., Cheikh-Ali, Z., Liebisch, T., Maciá-Vicente, J. G., Bode, H. B., & Piepenbring, M. (2016). Distinguishing commercially grown Ganoderma lucidum from Ganoderma lingzhi from Europe and East Asia on the basis of morphology, molecular phylogeny, and triterpenic acid profiles. Phytochemistry, 127, 29–37. ()
- Jin, X., Ruiz Beguerie, J., Sze, D. M.-Y., & Chan, G. C. F. (2016). Ganoderma lucidum (reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews , 4, CD007731. ()
- Jin, Z., Wang, Y., Ren, X., Xie, H., Gao, Y., Wang, L., & Gao, S. (2015). Pharmacokinetics and oral bioavailability of ganoderic acid A by high performance liquid chromatography-tandem mass spectrometry. International Journal of Pharmacology, 11(1), 27–34. ()
- Jun, L. (2002). Effect of radiotherapy combined with a medicine Lingzhi-912 on treatment of esophageal cancer. Journal of the Fourth Military Medical University, 23, 278–280. ()
- Klupp, N. L., Chang, D., Hawke, F., Kiat, H., Cao, H., Grant, S. J., & Bensoussan, A. (2015). Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database of Systematic Reviews , 2, CD007259. ()
- Loyd, A. L., Barnes, C. W., Held, B. W., Schink, M. J., Smith, M. E., Smith, J. A., & Blanchette, R. A. (2018). Elucidating “lucidum”: Distinguishing the diverse laccate Ganoderma species of the United States. PloS One, 13(7), e0199738. ()
- Loyd, A. L., Richter, B. S., Jusino, M. A., Truong, C., Smith, M. E., Blanchette, R. A., & Smith, J. A. (2018). Identifying the “mushroom of immortality”: Assessing the Ganoderma species composition in commercial reishi products. Frontiers in Microbiology, 9, 1557. ()
- Noguchi, M., Kakuma, T., Tomiyasu, K., Kurita, Y., Kukihara, H., Konishi, F., Kumamoto, S., Shimizu, K., Kondo, R., & Matsuoka, K. (2008). Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: A double-blind, placebo-controlled randomized and dose-ranging study. Asian Journal of Andrology, 10(4), 651–658. ()
- Noguchi, M., Kakuma, T., Tomiyasu, K., Yamada, A., Itoh, K., Konishi, F., Kumamoto, S., Shimizu, K., Kondo, R., & Matsuoka, K. (2008). Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms. Asian Journal of Andrology, 10(5), 777–785. ()
- Oka, S., Tanaka, S., Yoshida, S., Hiyama, T., Ueno, Y., Ito, M., Kitadai, Y., Yoshihara, M., & Chayama, K. (2010). A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas. Hiroshima Journal of Medical Sciences, 59(1), 1–6. ()
- Singh, A. B., Gupta, S. K., Pereira, B. M., & Prakash, D. (1995). Sensitization to Ganoderma lucidum in patients with respiratory allergy in India. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology, 25(5), 440–447. ()
- Tang, W., Gao, Y., Chen, G., Gao, H., Dai, X., Ye, J., Chan, E., Huang, M., & Zhou, S. (2005). A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. Journal of Medicinal Food, 8(1), 53–58. ()
- Tawasri, P., Ampasavate, C., Tharatha, S., Chiranthanut, N., & Teekachunhatean, S. (2016). Effect of oral coadministration of ascorbic acid with ling zhi preparation on pharmacokinetics of ganoderic acid A in healthy male subjects: A randomized crossover study. BioMed Research International, 2016, 2819862. ()
- Teekachunhatean, S., Sadja, S., Ampasavate, C., Chiranthanut, N., Rojanasthien, N., & Sangdee, C. (2012). Pharmacokinetics of ganoderic acids A and F after oral administration of ling zhi preparation in healthy male volunteers. Evidence-Based Complementary and Alternative Medicine: eCAM, 2012, 780892. ()
- Wachtel-Galor, S., Szeto, Y.-T., Tomlinson, B., & Benzie, I. F. F. (2004). Ganoderma lucidum (’Lingzhi'); Acute and short-term biomarker response to supplementation. International Journal of Food Sciences and Nutrition, 55(1), 75–83. ()
- Wachtel-Galor, S., Yuen, J., Buswell, J. A., & Benzie, I. F. F. (2012). Ganoderma lucidum (Lingzhi or Reishi): A Medicinal Mushroom. In I. F. F. Benzie & S. Wachtel-Galor (Eds.), Herbal Medicine: Biomolecular and Clinical Aspects. CRC Press/Taylor & Francis. ()
- Wang, X., Liu, R., Sun, J., Guan, S., Yang, M., Bi, K., & Guo, D. (2007). HPLC method for the determination and pharmacokinetic studies of four triterpenoids in rat plasma after oral administration of Ganoderma lucidum extract. Biomedical Chromatography: BMC, 21(4), 389–396. ()
- Wang, X. M., Guan, S. H., Liu, R. X., Sun, J. H., Liang, Y., Yang, M., Wang, W., Bi, K. S., & Guo, D. A. (2007). HPLC determination of four triterpenoids in rat urine after oral administration of total triterpenoids from Ganoderma lucidum. Journal of Pharmaceutical and Biomedical Analysis, 43(3), 1185–1190. ()
- Wu, D. T., Deng, Y., Chen, L. X., Zhao, J., Bzhelyansky, A., & Li, S. P. (2017). Evaluation on quality consistency of Ganoderma lucidum dietary supplements collected in the United States. Scientific Reports, 7(1), 7792. ()
- Zeng, P., Guo, Z., Zeng, X., Hao, C., Zhang, Y., Zhang, M., Liu, Y., Li, H., Li, J., & Zhang, L. (2018). Chemical, biochemical, preclinical and clinical studies of Ganoderma lucidum polysaccharide as an approved drug for treating myopathy and other diseases in China. Journal of Cellular and Molecular Medicine, 22(7), 3278–3297. ()
- Zhang F. F., & Liu R. M. (2019). [Pharmacokinetics of ganoderic acids]. China Journal of Chinese materia medica, 44(5), 905–911. ()
- Zhang, Q., Zuo, F., Nakamura, N., Ma, C.-M., & Hattori, M. (2009). Metabolism and pharmacokinetics in rats of ganoderiol F, a highly cytotoxic and antitumor triterpene from Ganoderma lucidum. Journal of Natural Medicines, 63(3), 304–310. ()
- Zhang, Y., Lin, Z., Hu, Y., & Wang, F. (2008). Effect of Ganoderma lucidum capsules on T lymphocyte subsets in football players on “living high-training low.” British Journal of Sports Medicine, 42(10), 819–822. ()
- Zhao, H., Zhang, Q., Zhao, L., Huang, X., Wang, J., & Kang, X. (2012). Spore powder of ganoderma lucidum improves cancer-related fatigue in breast cancer patients undergoing endocrine therapy: A pilot clinical trial. Evidence-Based Complementary and Alternative Medicine: eCAM, 2012, 809614. ()
- Zhong, L., Yan, P., Lam, W. C., Yao, L., & Bian, Z. (2019). Coriolus versicolor and Ganoderma lucidum Related natural products as an adjunct therapy for cancers: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology, 10, 703. ()